The El Escorial criteria: Strengths and weaknesses

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 16, Issue 1-2, 2015, Pages 1-7

  Agosta, Federica ^a   Al Chalabi, Ammar ^b   Filippi, Massimo ^a   Hardiman, Orla ^d   Kaji, Ryuji ^e   Meininger, Vincent ^f   Nakano, Imaharu ^g   Shaw, Pamela ^h   Shefner, Jeremy ⁱ   Van Den Berg, Leonard H ^j   Ludolph, Albert ^c  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF ULM   (Germany)

^d TRINITY COLLEGE DUBLIN   (Ireland)

^e TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g JICHI MEDICAL UNIVERSITY   (Japan)

^h UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁱ SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^j UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

ALS; El Escorial

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DIFFUSION TENSOR IMAGING; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; EL ESCORIAL CRITERIA; ELECTROPHYSIOLOGY; FAMILIAL DISEASE; FRONTOTEMPORAL DEMENTIA; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; NEUROIMAGING; NEUROLOGIC EXAMINATION; PATHOPHYSIOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; STANDARDS;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS AS TOPIC; FRONTOTEMPORAL DEMENTIA; HUMANS; NEUROIMAGING; NEUROLOGIC EXAMINATION; SEVERITY OF ILLNESS INDEX;

EID: 84925609979     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2014.964258     Document Type: Article

References (57)

1. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial 'Clinical limits of amyotrophic lateral sclerosis'workshop contributors. J Neurol Sci. 1994; 124: 96-107.
2. Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Disease. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000; 1: 293-9.
3. de Carvalho M, Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler. 2009; 10: 53-7.
4. Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. Arch Neurol. 2012; 69: 1410-6.
5. Cellura E, Spataro R, Taiello AC, La Bella V. Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin Neurol Neurosurg. 2012; 114: 550-4.
6. Davenport RJ, Swingler RJ, Chancellor AM, Warlow CP. Avoiding false-positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry. 1996; 60: 147-51.
7. Mitchell JD, Callagher P, Gardham J, Mitchell C, Dixon M, Addison-Jones R, et al. Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)-a 20-year review: can we do better? Amyotroph Lateral Scler. 2010; 11: 537-41.
8. Chiò A, Borghero G, Calvo A, Capasso M, Caponnetto C, Corbo M, et al. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology. 2010; 75: 619-25.
9. Chiò A, Mora G, La Bella V, Caponnetto C, Mancardi G, Sabatelli M, et al. Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. Muscle Nerve. 2011; 43: 189-95.
10. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial. Lancet Neurol. 2007; 6: 1045-53.
11. Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009; 66: 235-44.
12. Miller RG, Petajan JH, Bryan WW, Armon C, Barohn RJ, Goodpasture JC, et al. A placebo-controlled trial of recom-binant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Ann Neurol. 1996; 39: 256-60.
13. Miller RG, Moore DH 2nd, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 2001; 56: 843-8.
14. Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology. 2007; 69: 776-84.
15. Pascuzzi RM, Shefner J, Chappell AS, Bjerke JS, Tamura R, Chaudhry V, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010; 11: 266-71.
16. Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al. A clinical trial of creatine in ALS. Neurology. 2004; 63: 1656-61.
17. Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010; 9: 481-8.
18. Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011; 17: 1652-6.
19. Byrne S, Bede P, Elamin M, Kenna K, Lynch C, McLaughlin R, et al. Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2011; 12: 157-9.
20. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002; 3: 15-21.
21. Chiò A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology. 2002; 59: 99-103.
22. Wijesekera LC, Mathers S, Talman P, Galtrey C, Parkinson MH, Ganesalingam J, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology. 2009; 72: 1087-94.
23. Ince PG, Evans J, Knopp M, Forster G, Hamdalla HH, Wharton SB, et al. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology. 2003; 60: 1252-8.
24. Chen A, Weimer L, Brannagan T 3rd, Colin M, Andrews J, Mitsumoto H, et al. Experience with the Awaji Island modifications to the ALS diagnostic criteria. Muscle Nerve. 2010; 42: 831-2.
25. Okita T, Nodera H, Shibuta Y, Nodera A, Asanuma K, Shimatani Y, et al. Can Awaji ALS criteria provide earlier diagnosis than the revised El Escorial criteria? J Neurol Sci. 2001; 302: 29-32.
26. Schrooten M, Smetcoren C, Robberecht W, van Damme P. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol. 2011; l70: 79-83.
27. Filippi M, Agosta F, Abrahams S, Fazekas F, Grosskreutz J, Kalra S, et al. EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases. Eur J Neurol. 2010; 17: 520-6.
28. Turner MR, Agosta F, Bede P, Govind V, Lule D, Verstraete E. Neuroimaging in ALS. Biomarkers in Medicine. Biomark Med. 2012; 6: 319-37.
29. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7: 263-9.
30. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioral variant of frontotemporal dementia. Brain. 2011; 134: 2456-77.
31. Agosta F, Valsasina P, Riva N, Copetti M, Messina MJ, Prelle A, et al. The cortical signature of amyotrophic lateral sclerosis. PLoS One 2012; 7: e42816.
32. Sach M, Winkler G, Glauche V, Liepert J, Heimbach B, Koch MA, et al. Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain. 2004; 127: 340-50.
33. van der Graaff MM, Sage CA, Caan MW, Akkerman EM, Lavini C, Majoie CB, et al. Upper and extramotor neuron involvement in early motor neuron disease: a diffusion tensor imaging study. Brain. 2011; 134: 1211-28.
34. Agosta F, Pagani E, Petrolini M, Sormani MP, Caputo D, Perini M, et al. MRI predictors of long-term evolution in amyotrophic lateral sclerosis. Eur J Neurosci. 2010; 32: 1490-6.
35. Menke RA, Abraham I, Thiel CS, Filippini N, Knight S, Talbot K, et al. Fractional Anisotropy in the Posterior Limb of the Internal Capsule and Prognosis in Amyotrophic Lateral Sclerosis. Arch Neurol. 2012; 69: 1493-9.
36. Raaphorst J, de Visser M, van Tol MJ, Linssen WHJP, van der Kooi AJ, de Haan RJ, et al. Cognitive dysfunction in lower motor neuron disease: executive and memory defi-cits in progressive muscular atrophy. J Neurol Neurosurg Psych. 2011; 82: 170-5.
37. van Blitterswijk M, Vlam L, van Es MA, van der Pol WL, Hennekam EA, Dooijes D, et al. Genetic overlap between apparently sporadic motor neuron diseases. PLoS One 2012; 7: e48983.
38. van den Berg-Vos RM, Visser J, Franssen H, de Visser M, de Jong JMBV, Kalmijn S, et al. Sporadic lower motor neuron disease with adult onset: classification of subtypes. Brain. 2003; 126: 1036-47.
39. van den Berg-Vos RM, Visser J, Kalmijn S, Fischer K, de Visser M, de Jong JMBV, et al. A long-term prospective study of the natural course of sporadic adult-onset lower motor neuron syndromes. Arch Neurol. 2009; 66: 751-7.
40. Van Rheenen W, van Blitterswijk M, Huisman MH, Vlam L, van Doormaal PT, Seelen M, et al. Hexanucleotide repeat expansions in C9orf72 in the spectrum of motor neuron diseases. Neurology. 2012: 79: 878-82.
41. Visser J, van den Berg RM, Franssen H, van den Berg LH, Wokke JHJ, de Jong JMBV, et al. Disease course and prognostic factors of progressive muscular atrophy. Arch Neurol. 2007; 64: 522-8.
42. Visser J, van den Berg-Vos RM, Franssen H, van den Berg LH, Vogels OJ, Wokke JHJ, et al. Mimic syndromes in sporadic cases of progressive spinal muscular atrophy. Neurology. 2002; 58: 1593-6.
43. Guennoc AM, Camu W, Corcia P. Awaji criteria: new diagnostic criteria for amyotrophic lateral sclerosis. Rev Neurol. 2013; 169: 470-5.
44. Hanby MF, Scott KM, Scotton W, Wijesekera L, Mole T, Ellis CE, et al. The risk to relatives of patients with sporadic amyotrophic lateral sclerosis. Brain. 2011; 134: 3454-7.
45. Al-Chalabi A, Lewis CM. Modeling the effects of penetrance and family size on rates of sporadic and familial disease. Human Heredity. 2011; 71: 281-8.
46. Byrne S, Heverin M, Elamin M, Bede P, Lynch C, Kenna K, et al. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: a population based case-control cohort study of familial and sporadic amyo-trophic lateral sclerosis. Ann Neurol. 2013; 74: 699-708.
47. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in non-coding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011; 72: 245-56.
48. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008; 40: 572-4.
49. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, van Deerlin VM, Trojanowski JQ, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010; 68: 857-64.
50. Dornblüth O. Anatomische Untersuchung eines Falles von amyotropher Lateralsklerose. Neurologisches Centralblatt. 1889; 23: 377-86.
51. Elamin M, Phukan J, Bede P, Jordan N, Byrne S, Pender N, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology. 2011; 76: 1263-9.
52. Elamin M, Bede P, Byrne S, Jordan N, Gallagher L, Wynne B, et al. Cognitive changes predict functional decline in ALS: a population based longitudinal study. Neurology. 2013; 80: 1590-7.
53. Phukan J, Elamin M, Bede P, Jordan N, Gallagher L, Byrne S, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2012; 83: 102-8.
54. Bede P, Elamin M, Byrne S, McLaughlin RL, Kenna K, Vajda A, Pender N, et al. Basal ganglia involvement in amyotrophic lateral sclerosis. Neurology. 2013; 81: 2107-15.
55. Brettschneider J, del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013; 74: 20-38.
56. Strong MJ, Grace GM, Freedman M, Lomen-Hoerth C, Woolley S, Goldstein LH, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioral syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009; 10: 131-46.
57. Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behavior changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15: 9-14.